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Increased mortality among people who inject drugs (PWIDs) is attributed in part to the higher 
prevalence of chronic viral infections, notably HIV-1 and HCV. Approximately 38 million people 
globally are currently living with HIV-1. Type 1 interferons are important host factors that 
respond to HIV-1 infection by upregulating many interferon-stimulated genes (ISGs) with 
diverse antiviral effects. ISGs that restrict HIV-1 in humans have been poorly characterized; 
however, they demonstrate potential to be small molecule inhibitors that target HIV-1 during 
various stages in the life cycle. Here, we aim to better understand ISGs important in controlling 
HIV-1 infection. Therefore, we enrolled 19 HIV-1 infected patients with uncontrolled viremia 
and administered peginterferon alpha 2b (IFN). RNAseq was performed on activated CD4+ T 
cells and ISGs up-regulated in at least 11/19 people were identified. Both BCL2L14 and CMPK2 
were identified as ISGs that were important in controlling HIV-1 in this cohort.  RNA 
interference demonstrated that the anti-HIV-1 effect of IFNα could be attributable to both 
CMPK2 and BCL2L14. This is the first study to comprehensively assess both CMPK2 and BCL2L14 
role’s in HIV-1 infection.  
 
Hepatitis C virus (HCV) remains another major global health epidemic, with approximately 70 
million infected worldwide. Approximately 25% of individuals infected with HCV spontaneously 
clear infection. These individuals mount responses that lead to subsequent control of future 
HCV infections. Although the ability to spontaneously control multiple HCV infections is not 
indicative of sterilizing immunity, it seems to provide protective immunity against future 
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reinfections. Here, we aim to better understand HCV- specific CD8+ and CD4+ T-cells by 
developing a high-parameter phenotypic flow cytometry panel. This panel will simultaneously 
assess 27 phenotypic markers, including many exhaustion markers, to fully characterize CD4+ 
and CD8+ T-cells in individuals who progress to chronic infection, in comparison to those who 
spontaneously clear multiple reinfections. This work aims to inform vaccine development by 
characterizing essential cytolytic T-cell (CTL) epitopes for controlling infection, identifying 
inhibitory marker/s, and characterizing rare T-cell populations that may be important in 
controlling HCV infection. Most importantly, this work is the first development of a high 
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Mechanisms of HIV Control 
Introduction 
HIV-1 infects 37 million people worldwide, killing roughly 1 million people per year. Life-saving 
antiretroviral therapy controls, but does not eliminate, the virus. Whereas an HIV-1 cure is 
necessary, a clearer understanding of the intracellular fate(s) of HIV-1 is essential before a 
potent cure can be designed. Indeed, the host cell has several mechanisms by which it can limit 
replication of HIV-1, and an elucidation of these mechanisms offers keen insights into HIV-1 
biology.  In that context, we have reviewed recent advances describing intracellular genes that 
restrict HIV-1.   
Innate Immunity: sensing and restriction 
Innate immunity has received considerable attention recently for its role in host defense and 
inflammation. As a simplification, shared molecular patterns on invading pathogens can be 
recognized by intracellular sensors, triggering a downstream cascade of gene regulation in 
processes that have been extensively reviewed elsewhere [1, 2].  Many of the upregulated 
genes in innate immune cascades are devoted to ridding the host cell of the pathogen and/or 
recruiting a targeted adaptive response. With viruses, viral nucleic acids and structural 
components are often recognized by pattern recognition receptors, whereas downstream 
antiviral effector molecules target replication within the cell [3-5]. A hallmark example of an 
innate immune pathway with potent antiviral effects is the type 1 interferon pathway: upon 
sensing of viral nucleic acids, type 1 interferons are released. These in turn trigger the 
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transcription of hundreds of genes termed interferon-stimulated genes (ISGs), many of which 
directly constrain viral replication [6].  
HIV-1 is a retrovirus: productive infection of host cells requires that uncoated HIV-1 RNA is 
reverse transcribed into a DNA provirus that is then integrated into the host cell’s genome. 
Conceptually, we have divided our review into restriction that occurs prior to HIV-1 integration 
and restriction that occurs post-integration (Figure 1.1). This conceptual division is to stress 
that pre-integration restriction necessarily occurs in cells that are not yet infected, whereas 
restriction post-integration occurs in cells that are already infected. We have also described the 
key adaptive measures that have evolved in HIV-1 to overcome restriction (Table 1.1).  
IFITM 
The interferon-induced transmembrane gene family (IFITM), comprising IFITM1, IFITM2, and 
IFITM3, restrict a broad panoply of viruses from entering the host cell [7]. The IFITM family are 
ISGs. IFITM1 was the first in this group to be discovered in an RNA silencing screen of ISGs that 
conferred resistance to Influenza A, West Nile, and dengue viruses [8]. IFITM1 is mostly found 
on the plasma membrane and has a role in blocking entry of HIV-1 virions [9]. In contrast, 
IFITM2 and -3 are largely localized to the late endosome and lysosomes [10, 11]. The IFITM 
genes are thought to inhibit HIV-1 entry by changing the composition and curvature of the 
plasma membrane, perhaps reducing its fluidity, thereby interfering with a phenomenon known 
as hemifusion [12, 13]. Hemifusion is essential for the incorporation of an HIV-1 virion into a 
target cell [14]. Intriguingly, although restriction of HIV-1 entry occurs pre-integration, there are 
two reports suggesting a role post-integration: Compton et al. found that the presence of 
IFITM3 in HIV-1 infected cells decreased transmission of HIV-1 to target cells [15]. Moreover, 
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time-lapse microscopy has shown that IFITM3 functions by decreasing fusion between the 
infected and uninfected target cell by affecting the virus membrane. Yu et al. confirmed that 
IFITMs were incorporated into HIV-1 virions and interacted with the envelope protein Env to 
restrict HIV-1 infection [16].  
There is evidence that certain HIV-1 variants may be resistant to the restriction of IFITM 
proteins. In particular, transmitter/founder viruses have been found to be more resistant to 
IFITM restriction than viruses isolated from later times during infection; the later viruses may 
gain sensitivity as a result of escape from concomitant neutralizing antibody responses [17], 
although this in turn raises the question as to the relative relevance of IFITM as an in vivo 
restriction mechanism compared to antibody-driven selection.    
TRIM5α and TRIM22 
Tripartite motif 5α (TRIM5α), the longest splicing isoform of TRIM5 gene, was identified as a key 
molecule in old world monkeys that confers potent resistance against HIV-1 [18]. Among the 
large family of TRIM proteins consisting of over 70 family members in the human genome, 
TRIM5, TRIM11, TRIM15, TRIM19, TRIM22, TRIM28, and TRIM31 all have been described as 
having antiretroviral activity, although the human TRIM5α only confers modest resistance to 
HIV-1 [19-22]. It is thought, then, that TRIM proteins are required to prevent cross-species 
transmission of retroviruses [23]. 
TRIM proteins are multi-domain proteins defined by an N-terminal RING finger with E3 
Ubiquitin ligase activity, one or two B-box domain(s), and a coiled-coil (RBCC) domain [19]. 
Some of the TRIM genes, including TRIM5α, also possess a C-terminal PRY/SPRY (SPla and the 
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RYanodine Receptor) domain that is important for HIV-1 capsid recognition [24]. TRIM5α acts at 
multiple levels to restrict HIV-1 replication. It specifically binds the capsid (CA) lattice of HIV-1 
and induces premature disassembly of viral particles, accompanied by proteosomal-
degradation of viral components such as integrase [25]. TRIM5α has also been found to 
promote autophagic degradation of retroviruses by interacting with Atg8 proteins [26]. More 
recent studies show that TRIM5α inhibits HIV-1 infection by sensing the retrovirus capsid 
lattice, eliciting an innate immune response [27]. Interaction with the capsid lattice enhances 
TRIM5α RING-associated E3-Ub ligase, which in turn promotes the synthesis of free Lys63-
linked Ub chains that bind to the TAK1 kinase complex. TAK1 ubiquitination leads to nuclear 
translocation of the transcription factors NF-κB and AP-1 that result in type 1 IFN and other pro-
inflammatory cytokines [28] [29], broadly inducing an antiviral state. 
Whereas the TRIM5α homolog in humans does not inhibit HIV-1 well, TRIM22, a human paralog 
of TRIM5α, is involved in type I IFN-mediated restriction of HIV-1 replication [30, 31].  TRIM22 
inhibits HIV-1 replication by interfering with Tat-and NF-ĸB-independent LTR-driven 
transcription, and by preventing Sp1 binding to the HIV-1 promoter [32, 33]. TRIM22 may also 
interfere with virion assembly and release by preventing the trafficking and budding of Gag 
proteins and Gag-containing virus particles [30].   
Notably, because human TRIM5α has only modest activity against HIV-1, it does not drive 
adaptation in the virus.  However, several reports have suggested that HIV-1 could acquire 
adaptive mutations in the capsid gene, among others, in the setting of an engineered TRIM5α 




SAMHD1 (Sterile alpha motif and histidine-aspartate domain containing protein 1) was 
discovered in 2011 as a restriction factor by two independent groups using a mass spectrometry 
pull-down approach to identify proteins that co-immunoprecipitated with the viral protein x 
(Vpx) present in HIV-2, but not HIV-1 [36, 37]. SAMHD1 is expressed at high levels in myeloid-
derived cells and in resting CD4+ T cells that are refractory to HIV-1 infection [36, 38, 39]. 
However, SAMHD1 is inducible by type I IFN in monocytes, but not in dendritic cells or resting 
CD4+ T cells [40]. SAMHD1 comprises three regions, the N-terminus sterile alpha motif (residues 
1–109), a catalytic histidine aspartate core domain (residues 110–599), and the C-terminus 
(residues 600–626) [41]. The catalytic core domain has 2’-deoxynucleoside 5’-triphosphate 
triphosphohydrolase (dNTPase) activity that is believed to restrict HIV-1 by diminishing the 
intracellular pool of available dNTP in immune cells needed for cDNA synthesis during reverse 
transcription [42-44]. The anti-HIV-1 activity of SAMHD1 is negatively modulated by 
phosphorylation at residue Thr-592, and the phosphomimetic mutation T592E impairs dNTPase 
activity [45]. Indeed, dNTP levels are elevated in SAMHD1-deficient cells, whereas reduced dNTPs 
lead to an attenuation of reverse transcription [46-48].  
Another feature of human SAMHD1 is that it exhibits metal-dependent 3'→5' exonuclease 
activity against single-stranded DNAs and RNAs in vitro, suggesting that it may bind to and 
degrade HIV-1 RNA [49]. Ryoo and colleagues created several SAMHD1 mutants that exclusively 
retained either their exonuclease activity or their dNTPase activity and showed that the 
exonuclease alone was sufficient to partially restrict HIV-1 [50].  
Restriction is overcome by Vpx in HIV-2 through interactions with the host Ub ligase adaptor 
DCAF1 that promotes SAMHD1 degradation [36, 37]. Whether HIV-1 has evolved adaptations to 
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counter SAMHD1 is still not well understood, although recently Kyei et al. reported that HIV-1 
might neutralize SAMHD1 in macrophages in concert with the cell cycle regulator cyclin L2 [51].  
There is suggestive evidence for the clinical relevance of SAMHD1: the gene is mutated in a 
subset of patients suffering from Aicardi-Goutières syndrome (AGS), and monocytes from 
patients with AGS appear exquisitely susceptible to HIV-1 infection, in contrast to monocytes 
from healthy persons [52]. 
APOBEC3 
Apolipoprotein B editing complex 3 (APOBEC3) family members are cytidine deaminases that 
include APOBEC3A-H [53, 54]. They are induced by Type I IFN and most play important roles in 
control of multiple retroviruses through RNA binding or through deamination of single-stranded 
DNA (ssDNA) [53]. APOBEC3 proteins are expressed variably in CD4+ and CD8+ T cell subsets, B 
cells, and myeloid cells [55]. APOBEC3G exerts a dominant antiviral effect in CD4+ T cell subsets 
[56], and in macrophages and primary CD4+ T cells shows more potent restriction of HIV-1 than 
the combined effect of APOBEC3F and APOBEC3DE [57]. The APOBEC3 family members restrict 
HIV-1 by hypermutating its genome, resulting in premature stop codons and defective 
proviruses that are incapable of propagating infection [58, 59]. APOBEC3G, for example, acts by 
temporarily inhibiting the reverse transcription step and deaminating C→U on the minus strand 
of the DNA, leading to a mismatch pairing of a G→A on the plus strand, thus causing genomic 
mutations [60]. Hypermutation leads to HIV-1 restriction in at least two ways: i) the host cell 
recognizes ssDNA as aberrant and degrades it [61]; and ii) proviral DNA is integrated as a 
defective provirus that is no longer capable of producing infectious virions, usually due to 
premature stop codons [62]. The restrictive activity of APOBEC3G depends on its encapsidation 
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in the budding virion, mediated by the nucleocapsid domain of Gag molecules: upon virion 
fusion with a target cell, the viral RNA, reverse transcriptase, integrase, and APOBEC3G are 
released into the cytosol, allowing restriction to occur in the target cell [63, 64]. In addition, 
APOBEC3F and -G may exert antiretroviral activities that are independent of their deaminase 
functions by interfering with reverse transcription, either terminating the synthesis of the 
minus-strand or preventing tRNA molecules from binding HIV-1 nucleic acids. 
HIV-1 has developed a significant adaptation to APOBEC3 restriction: the accessory protein Vif 
triggers the degradation of APOBEC3 proteins through polyubiquitination and proteasomal 
degradation [65-67]. Ubiquitination occurs by the recruitment of a Cullin 5–based E3 ubiquitin 
ligase complex consisting of elongin B, elongin C, and Rbx-1. The in vivo relevance of APOBEC3G 
is evident in recent reports showing that the HIV-1 latent reservoir in patients treated with 
antiretrovirals contains a large number of APOBEC3G hypermutated sequences [68, 69, 65]. 
Collectively, human studies suggest that the battle between HIV-1 and APOBEC3 is not 
concluded. Whereas the latent reservoir is largely defective, there exist replication competent 
viruses that impede an HIV-1 cure. Similarly, Vif efficiently blocks APOBEC3 genes, but is 
insufficient in terminating all hypermutation. The latter point is promising for strategies aimed 
at enhancing inactivation of proviruses. 
MX2 
The IFN-inducible myxovirus resistance 2 (MX2/MXB) is a member of a family of dynamin-like 
GTPases that includes human MX1/MXA, another well-known IFN-inducible inhibitor of a broad 
range of viruses. In 2013, the anti-HIV-1 activity of MX2 was described by three separate groups 
[70-72]. MX2 appears to act at a late post-entry step prior to integration of proviral DNA, 
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possibly through inhibition of nuclear import following reverse transcription, or by inhibiting 
the uncoating of HIV-1 [70, 71, 73]. It has also been proposed that MX2 could decrease 
integration of nascent viral DNA, leading to nuclear accumulation of 2’ LTR circles [70]. MX2 
interacts with the HIV-1 capsid and may be dependent on CypA: substitutions in the CypA 
binding loop at positions 86-88 and 92 disrupt the binding of MX2 and capsid protein [74]. 
Similarly, treatment with cyclosporine, which blocks the CypA interaction with capsid, reduces 
the restrictive ability of MX2 [72]. 
There is little in vivo data to support the relevance of MX2 in HIV-1 restriction, although our 
group has found strong evidence that interferon administration to HIV-1 infected persons led to 
MX2 induction and proportional declines in plasma HIV-1 RNA in activated CD4+ T cells.  In 
addition, mutations in the HIV-1 capsid protein and in integrase confer resistance to MX2 [75]. 
It is yet to be understood how the potency of MX2 compares with other interferon-inducible 
HIV-1 restriction factors in humans. 
SLFN11 
SLFN11 belongs to the Schlafen family of mouse and human proteins implicated in the control 
of cell proliferation, immune responses, and the regulation of viral replication [76]. It has 
recently been identified as inducible by type 1 IFNs [77]. SLFN11 does not inhibit reverse 
transcription, DNA integration, production and nuclear export of viral RNA, or budding or 
release of viral particles. Its role in inhibition is one of the first to be associated with codon bias, 
inhibiting the expression of viral proteins. It binds to tRNAs, limiting their availability, thereby 
leading to a decrease in protein synthesis [77]. SLFN11 was also recently found to be 
significantly elevated in CD4+ T cells from elite HIV controllers as compared to non-controllers 
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and ART-suppressed individuals, suggesting that SLFN11 may play a role in the suppression of 
HIV-1 in vivo [78]. However, it is not clear whether the effects of SLFN11 are sufficiently robust 
to promote adaptation in HIV-1 in vivo.  
MARCH8 
Recently, Tada et al. reported that the membrane-associated RING-CH8 (MARCH8) E3 ubiquitin 
ligase, a gene that is highly expressed in terminally differentiated myeloid cells such as 
macrophages and dendritic cells, possesses potent anti-HIV-1 activity in vitro [79]. The antiviral 
effect of MARCH8 was discovered serendipitously when the investigators noted that the 
transduction efficiency of lentiviruses produced from MARCH8-expressing cells was several-fold 
lower than that of control lentiviruses. MARCH8 blocks the incorporation of HIV-1 envelope 
glycoprotein into virus particles, resulting in a substantial reduction in the efficiency of virus 
entry, thus inhibiting its infectivity.  Intriguingly, viruses are normally released, but are rendered 
non-infectious in the presence of MARCH8. Neither HIV-1 Vpr, Vpu nor Nef have detectable 
anti-MARCH8 activity, suggesting that HIV-1 lacks a counter-mechanism that dampens the 
effects of MARCH8. Studies are ongoing to determine the in vivo relevance of MARCH8, and 
whether HIV-1 can indeed adapt resistance to its effects. 
Tetherin 
Tetherin (Bone marrow stromal cell antigen-2 [BST-2]; CD317) is a restriction factor that was 
first identified in a microarray screen aimed at finding ISGs that are associated with the plasma 
membrane in cells that were not permissive for HIV-1 propagation [80]. Tetherin consists of an 
N-terminal cytoplasmic tail, a transmembrane helix, a coiled-coil ectodomain, and a C-terminal 
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glycosylphosphatidylinositol (GPI) membrane anchor. It is localized in lipid rafts at the plasma 
membrane, in the trans-Golgi network, and in early recycling endosomes [81]. Tetherin inhibits 
the release of nascent HIV-1 particles by tethering the budding virions at the cell surface [82]. 
Nascent virions anchored to the membrane are then internalized and degraded in the 
lysosome. Interestingly, the topology of tetherin is unique. When a mimic of tetherin was 
designed from unrelated proteins, HIV-1 was inhibited, demonstrating that the topology of 
tetherin, not the sequence, is key to its restrictive function. 
Another proposed role of tetherin in infection is its role as a viral sensor. It has been suggested 
that a budding virion could act as a pathogen-associated molecular pattern that is sensed by 
tetherin. As tetherin binds budding virions, clustering of tetherin dimers promotes the 
recruitment of TRAF2 and TRAF6, leading to activation of TAK1 and NF-κB and upregulation of 
proinflammatory cytokines such as CXCL10, IL-6 and IFN-gamma [83, 84]. The ability of tetherin 
to activate NF-κB requires multimerization [83].  
HIV-1 has evolved several viral proteins have evolved to antagonize tetherin: HIV-1 Vpu (in 
groups M and N) and Nef (in group O) [85, 80, 86]. Indeed, the role of tetherin as a broad 
antiretroviral is evident in that HIV-2 and SIV have evolved resistance to their host versions of 
tetherin [87]. HIV-1 Vpu, a small transmembrane protein, interacts directly with tetherin at the 
trans-Golgi network and targets it for proteasomal or lysosomal degradation [88, 89]. Deletion 
of Vpu results in tetherin-mediated retention of virions at the plasma membrane [80]. In 




In a study structured to find constitutively expressed restriction factors that are suppressed by 
Nef, Usami et al., discovered that SERINC3 and SERINC5 were both able to restrict HIV-1 
replication [90]. In Nef-deleted HIV-1 pseudotyped virus, the addition of SERINC5 significantly 
reduced infectivity. The amount of SERINC5 expression was directly associated with a 
quantitative loss of fusion of HIV-1 Δnef virions when co-expressed with a chimeric B-
lactamase-Vpr. To further support these effects, SERINC5 mRNA level was inversely correlated 
with a requirement of Nef for HIV-1 replication in several cell lines (Jurkat, 293T, MT4). 
SERINCs are cell surface proteins that function by incorporating serine into membrane lipids, 
most notably in sphingolipids and phosphatidylserine [91]. The lipid composition of the viral 
envelope is important for infectivity. Furthermore, SERINC5 inhibits the completion of reverse 
transcription of HIV-1 in the absence of Nef, which is an essential step prior to provirus 
integration [90]. Although the importance of SERINC3/5 can be inferred from their inhibition by 
Nef, more work is needed to understand the clinical relevance of these genes in HIV-1 infected 
persons. 
 Clinical Implications of HIV-1 Restriction Factors 
Studies of restriction factors offer insights into the key molecular determinants of HIV-1 
replication, and collectively outline a roadmap of HIV-1 vulnerabilities that could be targeted 
therapeutically. As an example, interferon alpha has been used to non-specifically target HIV-1 
in several small trials of HIV-1 infected persons, and has been as effective as a single, modestly 
active antiretroviral drug [92]. Presumably, the actions of interferon alpha are at least partially 
in inducing ISGs that directly act on HIV-1 in the cells that are most susceptible to infection, but 
it is certainly possible that interferon alpha also recruits cellular immune responses.  Although 
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interferon alpha may not add benefit to HIV-1 infected patients because of its side effects, it is 
compelling to consider that genes and pathways downstream of interferon administration may 
be specifically targeted to produce similar effects on HIV-1 replication.  We speculate that for 
HIV-1 infected patients who have suppressed viral replication with antiretrovirals, it may be 
possible to silence integrated proviruses by exploiting or mimicking the actions of post-
integration restriction factors.  
Another approach to HIV-1 treatment follows from its adaptation to host restriction factors by 
the use of accessory proteins. Since these genes appear to be essential for the virus to 
circumvent host innate immunity, enzymatic inhibition of the activities of these accessory 
proteins may restore the ability of the host to control HIV-1 using its suite of restriction factors. 
Indeed, there has been a push of small molecules into clinical trials that have been 
demonstrated to have high potency activity against HIV-1 accessory proteins [93,94].  
Conclusion 
To address the challenge of an HIV-1 cure, a better understanding is required of how HIV-1 
persists despite host cell restriction.  Presently, the science of restriction factors is moving from 
the bench to the bedside as we explore which restriction factors are active in HIV-1 infected 
persons, and what measures can be used to enhance restriction. Future HIV-1 cure trials may 






Mechanisms of Control in HCV 
The need for a HCV prophylactic vaccine despite recent development of Directly Acting 
Antivirals 
Hepatitis C virus (HCV) infection is an important global health crisis, with approximately 70 
million people infected worldwide [95]. During acute infection, many individuals remain 
asymptomatic and the long-term outcome of infection is determined. In the United States, only 
50% of individual’s are aware of their HCV status and are; therefore, at risk for disease 
progression due to untreated chronic HCV infection. Chronic infection can lead to liver cirrhosis 
and hepatoceullar carcinoma [96-97]. In efforts to combat the rising rate of HCV-associated 
liver disease, directly acting antivirals (DAAs) were developed and cure HCV infection in the 
majority of treated patients. However, eradication by DAAs is limited due to cost, the 
asymptomatic nature of HCV infection that leaves infected people unaware, reinfection after 
treatment, and limited treatment uptake in individuals who are most at risk of infection (people 
who inject drugs, PWID) [98]. Despite the ability of DAAs to cure HCV, they do not protect 
against future reinfections or completely reverse disease for individuals with advanced liver 
disease. These limitations demonstrate the importance of developing a HCV prophylactic 
vaccine.   
 
Understanding natural infection of HCV and induction of protective immunity 
Chronic infection is established in 75% of individuals who are infected with HCV, while the 
other 25% naturally clear the virus [98]. Spontaneous clearance of the primary infection doesn’t 
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provide sterilizing immunity against subsequent infection, but it does provide protective 
immunity. Humans who spontaneously clear the first infection clear 83% of reinfections [99]. 
Subsequent HCV infections are generally characterized by lower peak viral titers, with shorter 
duration of viremia until clearance compared to the primary infection [99]. Viral challenge 
studies in chimpanzees demonstrated similar low titers and decrease in duration of viremia 
with both homologous and heterologous viral challenges [100]. The control of reinfections in 
humans have been associated with cellular responses and development of broadly neutralizing 
antibodies [99].  
 
Evidence for Cellular responses in controlling HCV infection 
Characterization of cellular immune responses that distinguish chronic infection from 
spontaneous clearance are still poorly understood. Previous studies have shown that induction 
of broad and robust cellular immune responses is associated with spontaneous clearance [100-
103], in contrast to the low frequencies of HCV-specific CD8+ T-cells in those that remain 
chronically infected [104-109]. CD8+ T-cells are essential for the control of infection with a clear 
association between control of viremia and development of HCV-specific CD8+ T-cells [110-
111]. Durable CD4+ T-cell responses develop in individuals who spontaneously clear, although 
they develop in chronically infected individuals as well. Both CD4+ T-cell and CD8+ T-cell 
responses arise early infection regardless of outcome of infection, and may even persist during 
chronic infection; however, cellular responses are characterized as defective early in infection 
in those that persist [112]. Studies have demonstrated that in the chronic phase of infection, 
there was a gradual loss in both breadth and magnitude of cellular responses [113]. In 
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persistent infection, development of new epitope specificities after the first six months of 
infection were no longer seen. Altogether, this suggests the development of cellular responses 
is arrested within the first year of infection.  
 
Cellular Immune Responses in Reinfected Individuals 
The viral kinetics of reinfected subjects differ from those who progress to chronic infection. 
With exposure of new viruses, new T-cell responses were detected in all reinfected individuals, 
compared to one out of 12 subjects who progressed to chronicity. These data suggest that 
initial control of viremia is essential to generating new cellular immune responses, and not 
infection with new genotypically unique virus [113]. However, despite generation of new 
cellular responses in reinfected subjects, absolute protection was not guaranteed, as seen in 
some subjects that become persistently infected after initial control of viremia.  
 
Evasion of Cellular Responses mounted Against HCV by sequence variation 
HCV is highly variable and the quasispecies of variants differ from person to person. This can be 
attributed to the high level of virion turnover and the error prone HCV RNA polymerase, 
resulting in frequent mutations [114]. Studies have shown that CD8+ T cell escape early in 
infection plays a role in determining outcome, due to the low rate of amino acid substitutions 
seen early during longitudinal studies [115, 123]. The generation of mutations can have a 
deleterious, neutral, or advantageous effect on the virus by promoting evasion of cellular 
immune responses. It has been reported that in persistent infection there was a 16.7-fold 
higher likelihood of mutations within a T cell epitope compared to outside [113]. This evasion of 
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immune responses by mutating within the T-cell epitopes has negative effects for the host by 
decreasing MHC binding, impairing antigen processing or presentation, and affecting T-cell 
receptor engagement [116-123]. 
 
Other mechanisms of Evasion of Cellular Responses mounted Against HCV  
T- cell inhibitory receptors are increasing in importance in eliciting effector function in both 
CD8+ and CD4+ T-cells. One inhibitory marker of importance is programmed death-1 (PD-1). 
PD-1 surface levels are higher on HCV-specific T-cells in both the acute and chronic phase of 
individuals who fail to control HCV [113].  PD-1 levels on HCV-specific T-cells correlate with HCV 
RNA levels, and is also associated with progression to chronicity, independent of HCV RNA 
levels [124]. Upregulation of PD-1 in HCV infection is dependent on both the presence of pro-
inflammatory signals upon TCR engagement, and the presence of intact antigen [125-126]. 
Despite PD-1’s association with HCV RNA levels, data have shown that expression on HCV 
antigen-specific T-cells during the chronic phase greatly varied. In some cases, PD-1 levels 
remained low despite high viral titers during the chronic phase of infection. This low expression 
of PD-1 was associated with escape mutations in the T-cell epitope. PD-1 levels remained high 
on all T-cells with intact antigen, and mutated T-cell epitopes expressed high levels of PD-1 











Figure 1.1. Inhibition of HIV replication by known host restriction factors  
 
HIV-1 is inhibited by multiple restriction factors (blue) throughout its life cycle. IFITM proteins 
alter plasma membrane fluidity, inhibiting HIV-1 entry. TRIM5α prevents appropriate uncoating 
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of the capsid. SAMHD1 inhibits cDNA synthesis by limiting the amount of free 2′-
deoxynucleoside 5′-triphosphates (dNTPs) and possibly by its exonuclease activity (dashed 
lines). APOBEC3 proteins interfere with reverse transcription leading to uracilation of single-
stranded DNA (ssDNA), a mechanism known as hypermutation. MX2 interferes with nuclear 
import, limiting the integration of proviral DNA. SLFN11 inhibits the translation of essential 
proteins needed to form HIV-1 virions. MARCH8 inhibits the incorporation of Env proteins. 
TRIM22 inhibits the production and incorporation of Gag proteins and inhibits LTR-dependent 
transcription. Tetherin, SERINC3/5, and TRIM22 prevent the virion from successfully budding.  
Dashed lines indicate proposed mechanisms. The pink circle denotes reverse transcriptase and 














Table 1.1: Mechanisms of HIV-1 evasion 
















Identification of CMPK2 and BCL-G as Interferon 
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Type 1 interferons upregulate hundreds of interferon-stimulated genes (ISGs) that have diverse 
antiviral effects. ISGs that restrict HIV-1 in humans have been poorly characterized. Exogenous 
interferon-α decreases HIV-1 viremia so we hypothesized that observed decline in HIV-1 
viremia in people who receive exogenous interferon-alpha is due to the induction of ISGs that 
directly control HIV-1 in activated CD4+ T cells, the cells in which the virus chiefly replicates. To 
address this hypothesis, we previously published work characterizing putative ISGs that are HIV-
1 restriction factors. Briefly, activated CD4+T-cells CD3+/CD4+/CD38+/HLA-DR+) sorted from 
PBMCs taken from 19 HIV-1 infected patients with uncontrolled viremia before and after 
peginterferon alpha 2b (IFN) administration. RNAseq was performed on sorted activated CD4+ 
T cells and ISGs were identified in which Cytidine/Uridine Monophosphate Kinase 2 (CMPK-2) 
and Apoptosis facilitator Bcl-2-like protein 14 (BCL-G) were amongst the top hits that correlated 
in magnitude of induction with the subsequent decline in plasma HIV-1 viremia.  In vivo findings 
were confirmed in both MT4 and THP-1 cells; cell lines in which BCL-G and CMPK2 are highly 
expressed upon IFN induction. mRNA (measured by qPCR) and protein levels (measured by 
Western blot) were quantified pre and post- IFNα treatment (1000 IU/mL). RNA interference 
was used to test whether the anti-HIV-1 effect of IFNα could be attributed to the gene of 
interest. IFNα-mediated restriction of HIV was attenuated in cells transfected with siRNA 
against CMPK2 in comparison to the scrambled control. The effect was approximately ten-fold 
with this effect seen across a range of HIV inocula. CMPK2, a gene involved in maintenance of 
intracellular UTP/CTP, is an ISG with potential to restrict HIV-1 replication. Overexpression was 
used to test the anti-viral effect of BCL-G on HIV-1 infection. The effect was minimal at 
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approximately three-fold inhibition observed in comparison to the empty control vector. It was 
hypothesized that BCL-G may be restricting HIV-1 replication through inducing apoptosis in 
infected cells. Analysis of RNaseq results shows multiple co-expressed genes Pre-IFN, Post-IFN, 
and Post-ART that may aid in facilitating BCL-G’s restriction of HIV-1. Future work will focus on 
the mechanism underlying the antiviral effects of CMPK2 and BCL-G.  
Introduction 
HIV-1 infects 37 million people and contributes to approximately 1 million deaths per year. HIV-
1 is controlled by lifelong treatment with combination antiretroviral therapy (cART), which acts 
by suppressing viral replication. IFNs upregulate transcription of diverse ISGs with numerous 
antiviral functions. Administration of exogenous IFN to HIV-1 infected individuals results in a 
decline of viral RNA levels and cells harboring HIV-1 by upregulation of these antiviral host 
defense mechanisms [128]. Because of their potential to uncover steps in the viral life cycle that 
are vulnerable to interruption, other interferon-induced HIV-1 restriction factors such as 
SAMHD1, BST2, and MX2 have become the focus of considerable research. Previous studies 
suggest that not all interferon-induced HIV-1 restriction factor have been characterized. Our lab 
characterized BCL-G and CMPK2 as interferon-induced HIV-1 restriction factor [129].  
CMPK2 was first characterized as a pyrimidine nucleoside monophosphate kinase that localizes 
in the mitochondria, with a possible role in mitochondrial DNA depletion. CMPK2 was also 
shown to phosphorylate dUMP, dCMP, CMP, and UMP using ATP [130]. Intracellular levels of 
dUTP are detrimental to integration of HIV-1 proviruses. It was previously shown that in the 
presence of hUNG2 and high levels of dUTP, proviruses are highly uracilated, rapidly degraded, 
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and restricted from integrating [131]. We therefore hypothesized that CMPK2 may restrict HIV-
1 infection by maintenance of intracellular UTP/CTP. 
The role of BCL-G in the apoptotic pathway remains poorly understood. Initial studies of both 
the short and long isoforms of BCL-G demonstrated that BCL-Gs was capable of inducing 
apoptosis, while BCL-GL weakly induced apoptosis [132]. The presence of the BH2 domain in the 
long isoform negatively regulates the ability to induce apoptosis. However, others have shown 
that the expression of the long isoform of BCL-G correlated with apoptosis of CD4+ T-cells in SLE 
patients [133]. We therefore hypothesized that BCL-G may restrict HIV-1 infection by causing 
apoptosis either directly or indirectly of infected CD4+ T-cells. 
Materials and Methods 
Human subjects. Nineteen individuals with HIV/HCV co-infection were recruited and enrolled in 
a study of HIV and HCV viral kinetics pre-antiretroviral therapy (pre-ART). These subjects were 
admitted to Johns Hopkins Hospital and a single shot of peginterferon alpha 2b (PEG-IFN) was 
administered. Blood was collected from these individuals at 24, 48, 72 hours, 7 days, and 14 
days after IFN administration. The 19 individual’s received cART consisting of raltegravir, 
tenofovir, and emtricitabine, 14 days post IFN. When individuals had taken cART for >12 weeks 
and showed evidence of HIV-1 suppression, a second PEG-IFN injection was administered. 
Blood was collected 72 hours later.  
RNAseq and correlation between ISG upregulation and HIV-1 restriction. In the described 
cohort of 19 individuals, peripheral blood mononuclear cells (PBMCs) were collected Pre-IFN (0 
hrs) and post-IFN (24 hrs) treatment and activated (CD38+HLADR+) CD4+ T cells were FACS 
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sorted at each respective time point. RNA was extracted, cDNA libraries were prepped, and 
RNA sequencing was performed (RNAseq). Putative ISGs were defined using RNAseq data. 
Fragments per kilobase million (FPKM) values were calculated Pre-IFN and Post-IFN, and 
induction of genes were calculated by dividing Post-IFN FPKM values by the Pre-IFN FPKM 
values. Putative ISGs that were HIV-1 restriction factors were defined by performing spearman 
rank-correlation, adjusted for multiple comparisons using Benajami-Hochberg method [134] 
between ISGs and the observed viral load decline within 24 hours of PEG-IFN treatment.  
In Vitro HIV-1 Inhibition by IFN in multiple cell lines and measurement of HIV-1 production. 
Nine cell lines MT4, THP-1, CXCR4-U87, CCR5-U87, pATC, PM1, supT1, MT2, and A3.03 (NIH 
AIDS Reagent Bank) were spinoculated with varying concentrations of HIV-IIIB (NIH AIDS 
Reagent Bank). For each concentration, 200,000 cells were spinoculated with HIV-IIIB and RPMI 
containing 10% FBS for 2 hours at 1,200g in V-bottom plates. Cells were rested overnight at 3 
7°C and each well was split into two wells; one received treatment with 1,000 IU/mL of 
universal Type I IFN (PBL), while the other received no treatment. All cells were incubated for 
72 hours at 3  7 °C, and supernatants were collected for p24 measurements or TZM-bl assay to 
quantify luciferase activity. 10,000 TZM-bl luciferase reporter cells (NIH AIDS Reagent bank) 
were incubated with 100uL of supernatant and 100uL of DMEM containing 10% FBS and 
20ug/mL of DEA-Dextran for 48 hours at 3  7 °C. Cells were washed two times with 1x PBS and 
lysed using 50uL of 1X cell culture lysis buffer (Promega). After incubation for 10 minutes, 50uL 
of lysed cells were transferred to a Costar 96 well white, flat-bottom plate for reading by the 
luminometer. Luciferase activity was measured using the Luciferase assay kit (Promega). 
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Infection was calculated by dividing the luciferase reading for the IFN-treated wells by the 
untreated wells.  
Western Blots for measuring IFN induction, overexpression, and knockdown. MT4, THP-1, and 
293T/17 (NIH AIDS Reagent Bank) cell lines were used for western blot experiments. 750,000 
cells were plated in 6-well plates for 24 to 72hrs with varying concentrations of universal Type I 
IFN (0,100, and 1,000 IU/mL). Cells were lysed using 1x cell lysis buffer with protease inhibitors 
(1:100; Cell signal) on ice for 20 minutes. Cell lysates were collected after centrifugation at 4°C, 
for 20 minutes, at 13,000g. Protein was quantified using the BCA assay (Thermo) and 10ug of 
lysate was loaded into each well of 4012% bis-tris gels (NuPage). Blots were incubated for 1 
hour at room temperature in 5% MILK in 1x TBS + 0.1% Tween-20. Primary antibody for CMPK2 
(1:500, Novus), MX2 (1:1000, Novus), BCL-G (1:500, Novus), Anti-HA (1:1000, Thermo), and 
Actin (1:10,000, Thermo) was incubated overnight at 4°C in 5% MILK in 1x TBS + 0.1% Tween-
20. 
 In vitro knockdown experiments and measuring HIV-1 production. MT4 or THP-1 cells were 
transfected using electroporation with SMARTpool siGENOME siRNAs (Dharmacon) against our 
gene of interest or with scrambled negative controls at 100nM. Electroporation was done 
according to the manufacturer’s protocol using Amaxa Cell Line Nucleofector Kit V (Lonza). 
Immediately after electroporation, cells were rested in recovery media overnight at 37°C. 
200,000 cells were spinoculated with varying concentrations of HIV-IIIB in 50uL of RPMI 
containing 10% FBS for 2 hours at 1,200g in V-bottom plates. Cells were rested overnight at 
37°C and each well was split into two wells; one received treatment with 1,000 IU/mL of 
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universal Type I IFN (PBL), while the other received no treatment. All cells were incubated for 
48 hours at 3  7 °C, and supernatants were collected for the TZM-bl assay as described above.  
Overexpression of BCL-G, co-expression with HA-BCLXL and DN-Caspase9.  pCMV-Myc-BCL-G 
was previously cloned [129] and used alongside the empty pCMV-Myc_N (Clontech) vector as a 
control. 293T/17, COS-7, CXCR4-U87, and CCR5-U87 cell lines were plated at 750,000 cells per 
well in a 6-well plate. 24 hours later, the pCMV-Myc-BCL-G and empty control vector were 
transfected with lipofectamine 2000 according to the manufacturer’s protocol. Briefly, 2ug of 
each plasmid was transfected with 10uL of lipofectamine 2000 (Thermo) and incubated for 24, 
48, or 72 hours at 3  7 °C. HA-BCLXL and DN-Caspase 9 plasmids were gifted courtesy of Dr. 
Marie Hardwick at the Johns Hopkins School of Public Health. Co-expression experiments with 
pCMV-Myc-BCL-G was done using various amount of HA-BCLXL or DN-Caspase9 plasmids DNA 
(0ug-2ug) and transfected using Lipofectamine 2000 as described above. Cells were lysed for 
Western blot analysis as described above.  
Overexpression of BCL-G and the effect of MG132.  293T/17 cell line was plated at 750,000 cells 
per well in a 6-well plate. 24 hours later, the pCMV-Myc-BCL-G vector was transfected with 
lipofectamine 2000 according to the manufacturer’s protocol, and incubated for 48 hours at 3 
7°C. At 48 hours cells were either treated with 20uM of MG132 (Sigma) or left untreated for 4, 
8, 12, 24, or 48. After incubation, cells were lysed for western blot analysis as described above.  
Overexpression of BCL-G and quantitative real time PCR (qPCR) analysis of HIV-1 production.  
HIV production assays were performed by plating 10,000 cells of 293T/17, COS-7, CXCR4-U87, 
or CCR5-U87 cell lines in 96-well flat bottom plates and incubated overnight at 3  7 °C. Cells were 
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transfected using 0.5ug of pCMV-Myc-BCL-G or pCMV-Myc_N with 0.5uL of lipofectamine 2000 
per well. 48 hours later cells were infected with HIV-IIIB at varying concentrations in 100uL of 
DMEM and 10% FBS. 24 hours later supernatants were collected and 100uL were placed on 
TZM-bl cells for the HIV production assay. The cells were lysed using the ZR-Duet DNA/RNA 
Miniprep lysis buffer (Zymo Research). Reverse transcription was performed using Multiscribe 
reverse transcriptase kit (Thermo) according to the manufacture’s protocol. First minus strand 
transfer cDNA products and Poly adenylated tail were detected using the primer/probe 
combination as previously described, and samples were normalized to geometric means of the 
CT values from the housekeeping genes, GAPDH and RPLP0. Integrated HIV-1 DNA was 
quantified using Alu PCR as previously described [135]. Values were normalized to geometric 
means of the CT value for ERV3. qPCR reactions were performed in duplicates using the 
PrimeTime Gene Expression Master Mix (IDT).  
Statistical Analyses using R studio. All correlations were performed using the package “psych” in 
R version 3.6.1, using spearman rank correlations method. To identify the top genes that were 
co-expressed with BCL-G Pre-IFN, Post-IFN, or post-ART treatment, statistically significant 
spearman rank coefficients (p<0.05) were calculated between BCL-G and the observed genes. 
The post-ART timepoint FPKM values were obtained 72 hours post the second treatment with 
IFN as described above. Correlations were also performed to assess putative restriction factors 
between the fold-changes of putative ISGs and the intercellular associated HIV-1 DNA. Pairwise 
correlations were performed using the “corrplot” version 0.84. K-means clustering and principle 




HIV-1 restriction by IFN. In order to test the hypothesis that CMPK2 and BCL-G are ISGs that 
restrict HIV-1 infection from our previous work [129], we needed to test for robust IFN-
mediated restriction of HIV-1 replication in cell lines. We assayed nine cell lines by infecting 
them with a titrated range of replication-competent HIV-1 strain. Half of the wells for all cell 
lines were treated with IFN to test for inhibition of viral replication. MT4 and THP-1 cells 
supported the replication of HIV-1 lab strains, while being the most susceptible to IFN-mediated 
inhibition (Supplementary Figure 2.1).  
IFN inducibility of CMPK2 and the capacity to inhibit HIV-1 replication. We previously published 
data showing that CMPK2 mRNA was potently induced in THP-1 cells upon treatment with IFN 
[129]. We therefore studied CMPK2’s restriction capabilities in THP-1 cells. We confirmed 
CMPK2 induction at the protein level in THP-1 cells. MX2 was used as a positive control of IFN-
inducibility due to its identification as an ISG that restricts HIV-1 [70-72]. Both CMPK2 and MX2 
were best induced at 48 hours post treatment with IFN (Figure 2.1A). To determine if IFN-
mediated HIV-1 restriction could be attributed to CMPK2, we used siRNA to knockdown CMPK2 
expression in THP-1 cells. We transfected THP-1 cells with pooled siRNA against CMPK2 or with 
scrambled controls. THP-1 cells with our scrambled siRNA resulted in restriction of HIV-1 by IFN. 
This IFN-induced restriction of HIV-1 was attenuated in THP-1 cells transfected with siRNA 
against CMPK2. This effect was 10-fold and observed over a range of HIV-1 inoculum (Figure 
2.1B). HIV-1 titers in the untreated THP-1 cells were greater in the cells transfected with 
scrambled siRNA than in cells transfected with siRNA against CMPK2, supporting the role of 
CMPK2 as a restriction factor (Supplementary Figure 2.1). We further verified our results using 
western blots of the siRNA transfected THP-1 cells after knockdown and treatment with IFN to 
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ensure there was no upregulation of CMPK2. Our westerns showed no induction of CMPK2 
after treatment with IFN (Figure 2.1C). However, CMPK2 was upregulated in THP-1 cells that 
were transfected with scrambled siRNA and left untreated with IFN. This was most likely due to 
innate signaling responses in THP-1 due to transfection of siRNA.  
Mechanism of HIV-1 restriction by BCL-G.  
We previously demonstrated that overexpression of BCL-G using a myc-tag system resulted in 
restriction of HIV-1 replication in MT4 cells [129]. To develop a model in which we could test for 
restriction of replication-competent HIV strains, we tested CXCR4-U87 and CCR5-U87 cell lines 
that support replication of X4 and R5 tropic viruses, respectively. Myc-tagged BCL-G was 
overexpressed in CCR5-U87 cells (Supplementary Figure 2.2). CCR5-U87 cells were transfected 
with myc-tagged BCL-G for 48 hours, followed by a 24-hour infection with a range of HIV-IIIB 
inoculum and restriction of HIV-1 was measured using the TZM-bl assay. Our results showed 
minimal restriction of HIV-1 replication in comparison to the empty-myc control, with the 
greatest restriction of half a log (Figure 2.2A). ISGs act by restricting HIV-1 during various stages 
of its life cycle. It was previously reported that IFN treatment blocked the accumulation of all 
HIV cDNAs [136]. To assess if BCL-G restricts HIV-1 during reverse transcription of viral 
products, we ran qPCR to test for levels of first (minus) strand cDNA. CCR5-U87 cells were 
transfected with myc-tagged BCL-G, myc-tagged MX2 as a positive control, and the empty Myc-
tagged vector. Cells were infected with HIV-IIIB across two-fold dilutions of inoculum. Western 
blots images show similar degradation pattern as reported earlier (Supplementary Figure 2.3). 
Our results showed no significant accumulation in first stand cDNA products, indicating that 
BCL-G was not inhibiting HIV-1 during reverse transcription (Figure 2.2B). To measure the 
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amounts of HIV-1 virions in our assays, we ran qPCR quantifying HIV-1 RNA as described before 
[137]. Our results showed no significant difference in HIV-1 RNA across all conditions (Figure 
2.2C).  
The role of BCL-G in Apoptosis during HIV-1 Infection 
In our previous published work, we were unable to visualize BCL-G in MT4 cells upon treatment 
with IFN. In order to find antibodies most sensitive to detecting the BCL-G, we transfected the 
myc-tagged BCL-G vector into 293T/17 cells. Our results were visualized using western blots, in 
which we noticed a ladder pattern in wells with our BCL-G vector 48 and 96 hours post 
transfection (Figure 2.3A). This pattern has been previously described as protein degradation 
[138]. In attempts to reverse degradation of BCL-G, we treated 293T/17 cells with MG132, a 
commonly used proteasome inhibitor. MG132 had minimal effect on degradation of BCL-G, 
demonstrating that BCL-G was being degraded through a different pathway (Figure 2.3B). BCL-
G has previously been described to have both pro-apoptotic [133] and anti-apoptotic 
capabilities [139]. We therefore hypothesized that another mechanism BCL-G may restrict HIV-
1 infection is through the induction of apoptosis in infected cells. We obtained a HA tagged BCL-
XL vector from Dr. Marie Hardwick to test this hypothesis. BCL-XL has been described in 
literature to inhibit apoptosis by sequestering pro-apoptotic proteins [140]. To address the 
controversial literature describing BCL-G, we co-transfected the myc-tagged BCL-G vector with 
equivalent amounts of the HA-BCL-XL vector and visualized protein expression by western blot. 
Our results showed that BCL-G expression was increased in the presence of BCL-XL, providing a 
system in which BCL-G levels can be modulated (Figure 2.3C). Our data suggests that BCL-XL 
regulates BCL-G levels by either sequestering BCL-G or modulating BCL-G levels to either 
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enhance or diminish its downstream role. Further studies need to be done to understand this 
relationship in greater detail. 
Determining genes that relate to expression of BCL-G Pre-IFN, Post-IFN, and Post-ART.  
With the unclear role of BCL-G in initiating apoptosis in HIV-1 infected cells, we hypothesized 
that BCL-G’s expression might be dependent on other genes involved in the apoptosis pathway, 
during the Pre-IFN, Post-IFN, or Post-ART timepoints. To analyze genes that related to BCL-G 
Pre-IFN, we took FPKM values of all genes from the RNAseq dataset and correlated it BCL-G 
expression among all 19 individuals, and plotted the top ten significant genes (Figure 2.4A).  
Spearman rank coefficients were calculated and the top fifty statistically significant genes were 
analyzed (Figure 1.4B). Pairwise correlation analysis revealed clusters of related genes, and as 
expected, the top fifty genes were highly related within each other, with Spearman coefficients 
>0.6 or >-0.6. (Figure 2.4C). We further characterized clustering using the principal component 
analysis of FPKM values. There was distinct clustering of genes that negatively or positively 
correlated with BCL-G expression, as well as clusters of previously defined ISGs (Figure 2.4D). 
Interestingly, BCL-G was highly correlated with CMPK2, MX2, and LAMP3 Pre-IFN, which were 
all described as ISGs in previously published work. It was most highly correlated with LAP3, a 
cytosolic aminopeptidase, with a proposed role in apoptosis [141]. A heatmap analysis was 
performed with a clustering filter to demonstrate the highly related group of ISGs, seen in the 
PCA analysis (Supplementary Figure 2.4).  This analysis was performed for the Post-IFN 
timepoint by correlating the fold change of BCL-G with the fold change of all genes in our 
RNAseq data. Fold change was calculated by dividing the FPKM values Post-IFN by the FPKM 
values Pre-IFN. Pair-wise correlation analysis revealed clusters of related genes (Figure 2.4E). 
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Finally, the analysis was performed for the Post-ART timepoint, revealing another unique 
cluster of related genes (Figure 2.4F). This analysis demonstrated consistencies in relatedness 
of BCL-G with previously defined ISGs or members of the interferon response pathways, at all 
timepoints (i.e. IFI44, IFI6, IRF7, and MX2). It also revealed relatedness of BCL-G with other 
possible players in the apoptosis pathway at all timepoints (ie. LAP3 and tumor necrosis factor 
ligand superfamily member [TNFSF] proteins). The analysis suggests that BCL-G might be 
regulated alongside other genes that induce apoptosis or restriction in HIV-1. Further analysis 
will parse out the relatedness of these genes with BCL-G in vitro.  
Discussion and Limitations 
We were the first to annotate both CMPK2 and BCL-G as ISGs that restrict HIV-1 infection. 
CMPK2 has previously been described as an ISG, however its antiviral effect has been minimally 
explored. We aimed to explore the mechanism in which CMPK2 restricts HIV-1 infection. 
Because its enzymatic activity is directed towards phosphorylating dUMPs to dUTPs [130], we 
hypothesized that a possible mechanism for inhibiting HIV-1 infection was through increasing 
intracellular stores of dUTP. It was previously published that high pools of dUTP causes 
uracilation in HIV-1 proviruses, inhibiting its integration [131]. This mechanism would be a novel 
method in which an ISG restricts HIV-1 infection. Most importantly, inhibition pre-integration is 
critical, as the establishment of a latent reservoir is one of the largest hurdles to curing HIV-1. 
We faced many challenges when further studying the mechanism of restriction by CMPK2. The 
baseline induction of CMPK2 using siRNA was limiting our full study of its mechanism, so we 
developed a knockout cell line using CRISPR/Cas9 technology in THP-1 cell lines. Through the 
process of development, THP-1 cells died during the process of enriching clonal populations of 
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cells with knocked out CMPK2, likely due to toxicity from puromycin. The remaining cells began 
to differentiate into macrophages, a process that can classically be initiated using PMA in THP-1 
cells, most likely due to cellular stress.   
BCL-G was also previously described as an ISG without a known antiviral effect. Once we 
demonstrated its restriction of HIV-1 infection, we aimed to study the mechanism in which it 
restricts HIV-1 infection. BCL-G has a controversial role in the literature with some studies 
showing it is pro-apoptotic [132-133], while other studies show it is anti-apoptotic [139]. We 
hypothesized one mechanism in which BCL-G restricts HIV-1 is by inhibiting HIV-1 at various 
stages of its lifecycle, early in infection. Our data shows that BCL-G does not directly inhibit HIV- 
during first strand synthesis or by directly targeting HIV-1 RNA levels. We also tested for the 
accumulation of 2-LTR circles and integrated HIV-1 DNA, but our qPCR assays were insufficient 
at detecting both in infected CCR5-U87 cells. We then hypothesized another mechanism BCL-G 
restricts HIV-1 infection is through causing apoptosis of infected cells. When we first 
transfected BCL-G into 293T/17 cells and visualized our results using western blots, we noticed 
the laddering pattern of the protein, an indication of protein degradation. Our data suggests 
that BCL-G is not being degraded through the proteasome, and therefore another mechanism is 
causing its degradation. In collaboration with Dr. Marie Hardwick, we obtained tools to study 
the role of BCL-G in the apoptotic pathway. Previously, studies have shown that one 
mechanism pro-apoptotic genes are inhibited is through sequestration of pro-apoptotic genes 
by anti-apoptotic genes like BCL-XL. We tested the hypothesis that BCL-XL plays a role in 
regulating BCL-G in CCR5-U87 cells. Our results showed that BCL-XL increases expression of BCL-
G and its degradation products. Further work needs to be done in order to answer whether 
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BCL-XL is binding BCL-G itself, or signaling other players to induce expression. These results 
differ from previously published work in which co-transfection of BCL-G with BCL-XL shows no 
change in BCLG’s overall protein expression [132]. Whether BCL-G induces apoptosis remains 
inconclusive in the context of HIV-1 infection, due to limitations in our assay development. We 
experienced difficulty in developing an assay in which sufficient HIV-1 replication was 
quantified, and transfection with the transfection reagent alone, didn’t induce restriction of 
HIV-1. We assayed five different cell lines, with CCR5-U87 being the most promising cell line. 
Cells were counted from the HIV-1 restriction experiment above (Figure 3A) and cell counts 
were similar across all conditions (data not shown).  
The hypothesis that BCL-G may play a role in apoptosis is feasible given it has previously been 
shown to be enhanced in expression in pathogenic SIV infection in rhesus macaques, but not in 
nonpathogenic SIV infection in African green monkeys [142]. One notable difference between 
the pathogenic and nonpathogenic SIV strains is the loss of CD4+ T-cells in the pathogenic 
strain, similar to natural HIV-1 infection in humans. Many of the BCL-2 family members have 
been previously described to skew infected CD4+ T cells towards a pro- or anti-apoptotic fate. 
However, HIV-1 viral proteins have also developed mechanisms to inhibit various pro-apoptotic 
proteins. For example, the protein Nef has been shown to phosphorylate and inactivate the 
protein BAD, as well as downmodulate the expression of p53, inhibiting apoptosis [143]. BCL-G 
has been shown to have p53 binding sites, posing a mechanism in which BCL-G can indirectly 
inhibit HIV-1 infection [144]. Overall our results provide evidence that CMPK2 and BCL-G are 
ISGs that restrict HIV-1 infection, providing novel potential small molecule inhibitors as 






Figure 2.1A: CMPK2 and MX2 proteins are induced by IFN in THP-1 and MT4 cells. Western 
blots showing the upregulation of CMPK2 and MX2 after treatment with 1000 IU/mL of IFN for 




Figure 2.1B: Restriction of HIV in vitro is dependent on the IFN induction of CMPK2. 
Knockdown of CMPK2 was performed using pooled siRNA against CMPK2 in THP-1 cells (red) 
and was compared to the scrambled control (black). Cells were inoculated with varying 
concentrations of HIV-IIIB (115ng/mL-0ng/mL) and split to be treated with IFN or left untreated. 
Replication was quantified using the TZM-bl luciferase assy. IFN-induced restriction was 
calculated by log-transforming the difference in RLU values between the IFN-treated and 
untreated cells across each condition. *P,0.05; **P<0.01;***P<0.005.  
 
 
Figure 2.1C: CMPK2 knockdown using siRNA in THP-1 cells. Western blots showing the 
knockdown of siRNA in THP-1 cells. To ensure knockdown, THP-1 cells were treated with IFN at 




Figure 2.2A: Overexpression of BCL-G minimally inhibits HIV infection on CCR5-U87 cell. Cells 
were transfected with myc-tagged BCL-G (brown), the empty myc-vector (blue), transfection 
reagent (orange), or untransfected (pink) into CCR5-U87 cells. After 48 hours of transfection, 
cells were infected with 50, 25, or 0 ng of HIV-IIIB. Infection was measured using the TZM-bl 
assay. RLU values were log-transformed to indicate the level of HIV restriction (y-axis) across 
varying concentrations of HIV inoculum (x-axis). Each condition was tested in duplicate and the 







































Figure 2.2B: Overexpression of BCL-G-myc does not inhibit HIV RNA. CCR5-U87 cells were 
transfected with myc-tagged BCL-G, myc-tagged MX2, empty myc vector, transfection reagent 
alone (Lipo), or untransfected (cells) for 48 hours and infected with HIV-IIIB at varying inoculum. 
qPCR data showing the fold change of production of HIV-1 RNA in each condition, relative to 
housekeeping genes. All samples were run in triplicate and there were no statistically significant 
differences between the conditions.  
 
Figure 2.2C: Overexpression of BCL-G-myc does not inhibit production of first (minus) strand 
cDNA. CCR5-U87 cells were transfected with myc-tagged BCL-G, myc-tagged MX2, empty myc-
vector, transfection reagent alone (Lipo), or untransfected (cells) for 48 hours and infected with 
HIV-IIIB at varying inoculum. qPCR data showing the fold change of production of HIV-1 RNA in 
each condition, relative to housekeeping genes. All samples were run in triplicate and there 








































Figure 2.3A: BCL-G overexpression in 293T/17 cells causes degradation of BCL-G. 293T/17 cells 
were transfected with myc-tagged BCL-G, empty myc-tagged vector, pgMAX vector, or left 
untransfected. Western blots showing overexpression of BCL-G led to a degradation pattern at 





Figure 2.3B: MG132 treatment minimally rescues the degradation of BCL-G. 293T/17 cells 
were transfected with myc-tagged BCL-G and treated with MG132 at 4, 8, 12, 24, or 48 hours 
post-transfection. Western blots showing the degradation of BCL-G is minimally rescued by 
MG132.  
 
Figure 2.3C: Co-expression of BCL-G with BCL-XL causes an increase in protein levels of BCL-G 
and its degradation products. 293T/17 cells were transfected with myc-tagged BCL-G, HA-BCL-
XL, transfection reagent alone (Lipofectamine) or left untransfected for 24, 48, 72, or 96 hours. 
Western blots showing the protein expression of BCL-G and its degradation products are 







Figure 2.4A: Correlation plots of the top ten statistically significant genes. FPKM values of BCL-
G Pre-IFN were correlated with all FPKM values of our RNAseq dataset. The top ten statistically 
significant correlated genes are plotted above after analysis of spearman rank correlation 
coefficients. The genes are Lap3, DTYMK, MYD88, ZNF74P, RRP1, NUP50, SERPING1, IRF7, and 





































































Figure 2.4B: The top 50 correlated gene with BCL-G Pre-IFN. The top fifty statistically 
significant genes are plotted above. The blue circles indicate a positive correlation coefficient, 
and the red circles indicate a negative correlation coefficient.  
 
Figure 2.4C: Pairwise Correlation Plots for the top correlated genes Pre-IFN. Pairwise 
correlation plot of the top fifty genes revealed a hierarchy or relatedness among previously 





Figure 2.4D: Principle Component Analysis of the top 50 genes Pre-IFN. Principal component 

































































Figure 2.4E: Pairwise Correlation Plots for the top correlated genes Post-IFN. Pairwise 
correlation plot of the top fifty genes revealed a hierarchy or relatedness among previously 



















































































































































































































































Figure 2.4F: Pairwise Correlation Plots for the top correlated genes Post-ART. Pairwise 
correlation plot of the top fifty genes revealed a hierarchy or relatedness among previously 

























































































































































































































































Supplementary Figure 2.1: IFN-mediated restriction of HIV-1 in various cell lines. Cell lines 
were infected with varying concentrations of HIV-IIIB for 24 hours. Cells were then left 
untreated or treated with 1000 IU/mL of IFN for 72 hours. HIV replication was measured using 
supernatants for the p24 assay or the TZM-bl assay. Inhibitions was calculated by subtracting 
the log10 values of p24 or RLU values in IFN-treated cells from the untreated cells. The 




Supplementary Figure 2.2: IFN restriction of HIV-1 in THP-1 cells is dependent on CMPK2. THP-
1 cells were transfected with pooled siRNA against CMPK2 (red) or scrambled control (black). 
Cells were infected with varying concentrations of HIV-1 inoculum, and then split to either be 
treated with IFN (dashed) or left untreated (solid). Replication of HIV-1 was quantified using the 
TZM-bl assay. Analysis comparing the untreated cells transfected with siRNA against the 
scrambled control or CMPK2 was done by using t-tests. *P<0.05; **P<0.01. 
 
Supplementary Figure 2.3: Overexpression of myc-tagged BCL-G in CCR5-U87 cells causes 
degradation. CCR5-U87 cells were transfected with myc-tagged BCL-G, empty myc-tagged 
vector, HA-BCL-XL, transfection reagent alone (Lipofectamine) or left untransfected for 48 




Supplementary Figure 2.4: Heatmap Analysis of Top fifty genes Pre-IFN. Heatmap analysis 



































































































































































































































































High-dimensional flow cytometry analysis of T cell 
responses in individuals who clear multiple reinfections 













Hepatitis C virus infects over 70 million people world-wide. During acute infection, infected 
individuals have two outcomes. Most remain infected and progress to chronic infection, but 
some individuals spontaneously control infection, and do so repeatedly for multiple infections 
afterwards.  This divergence in infection outcome is in part attributed to differences in virus-
specific-T-cell responses. In particular, HCV-specific CD8+ T-cell effector responses are 
important for the control of HCV infection. However, the phenotypes of these cells are not fully 
defined.  To address this question, we developed a 28-color/30-parameter flow cytometry 
panel to simultaneously assess multiple inhibitory markers, chemokine receptors, and other 
phenotypic markers. This panel is the most comprehensive panel focused on T-cells to date and 
evaluates the differences in phenotypic marker expression in patients who spontaneously 
control infection compared to those who remain chronically infected. The overall goal of this 
panel is to fully understand the differences in HCV-specific CD8+ T-cells that render them 
efficient in naturally controlling HCV infection.  
Introduction 
HCV is a positive-stranded RNA virus that infects more than 70 million people worldwide [95]. 
This viral infection provides a unique model for understanding the causes of acute versus 
chronic infection. HCV infection results in progression to chronicity in approximately 75% of 
individuals and spontaneous clearance in the other 25% of individuals [98]. HCV-specific CD8+ 
T-cells play an important role in viral clearance through their cytolytic function. Previous studies 
showed that decreases in both HCV RNA titers and serum levels of alanine aminotransferase 
(ALT) correlated with CD8+ T-cell response [145-146]. Studies done in chimpanzees 
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demonstrated that the depletion of CD8+ T-cells prior to HCV challenge resulted in prolonged 
periods of high viremia. Clearance of HCV was seen once CD8+ T-cells recovered, producing 
HCV-specific responses [111]. Spontaneous clearance is also associated with sustained HCV-
specific CD8+ T-cell responses in both patients and chimpanzees, while chronicity is associated 
with weak and transient responses [101,112,145, 147]. The functionality of HCV-specific CD8+ 
T-cells is essential for controlling infection. Functionally impaired T-cells show decreased 
proliferation, cytolytic activity, and look phenotypically exhausted. This impairment is partially 
due to the expression of programmed cell death-1 (PD-1), T-cell immunoglobulin and mucin 
domain-containing molecule (TIM-3), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) 
[148-152]. However, many questions remain in understanding the complete picture on 
simultaneous receptor expression on HCV-specific-CD8+ T-cells and the correlation between 
viral clearance or persistence.  Here, we develop a high-parameter flow cytometry panel to fully 
assess receptor expression of many inhibitory markers including PD-1, CTLA-4, TIM-3, LAG-3, 
and KLRG1 on antigen specific CD8+ T-cells using HLA Class  multimers. This panel 
demonstrates differentiation between multiple phenotypic markers in reinfected subjects 
compared to chronic subjects, providing an essential tool in further understanding the 
differences in HCV outcome.   
Materials and Methods 
Study Participants. HCV infected subjects were obtained from the Baltimore Before and After 
Acute Study of Hepatitis (BBAASH), a longitudinal cohort study of PWID in Baltimore, Maryland. 
Participants were enrolled in this prospective study if they were at risk for HCV infection and 
were HCV-antibody negative. Individuals were consented and blood samples were collected 
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monthly, as previously described [153]. We identified people previously who had sufficient 
follow-up to evaluate the long-term outcome of infection [99]. HCV RNA testing was performed 
on plasma or serum samples using the COBAS Taqman RT-PCR quantitative assay (Roche). 
Defining Chronic and Reinfected Participants. HCV spontaneous controllers were previously 
defined [153] as individuals who were HCV RNA negative but HCV antibody positive for at least 
60 days. Chronic infection was defined by periods of continuous viremia with the same virus. 
Reinfection was defined by having new genetically unique periods of viremia, as defined by 
Core-E1 assay, in HCV spontaneous controllers. Subsequent reinfections were defined by having 
undetectable HCV RNA levels for at least 60 days.  
IFN--ELISpot Assay. HCV-specific CD8+ T-cell responses were identified using the interferon-
gamma (IFN-) ELIspot assay as previously described [154]. PBMC from participants were 
screened for the recognition of HCV-specific antigens using the previously described optimal 
HCV epitopes as well as pools of overlapping peptides.  
Flow Cytometry Staining Protocol. 
1. Thaw cryopreserved PBMCs with thawing medium (R50) using the drip method. Briefly, 
warm cryovials at 37°C in water for about 1 minute until frozen cells release from the 
bottom of the cryovial. Slowly drip 1mL of pre-warmed R50 into the cryovial and 
transfer to 15mL conical. Slowly drip 2mL R50, rest 1 minute, and continue until cells are 
resuspended in 15mL R50.  
2. Centrifuge cells 400 x g for 5 minutes 
3. Discard supernatant and wash cells once in chilled PBS 
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4. Centrifuge cells 400 x g for 5 minutes 
5. Resuspend cells in 100uL Live/Dead Blue (diluted 1:200 in PBS) and transfer cells to 96-
well V-bottom plate.  
6. Incubate 20 min at 4°C in the dark 
7. Bring staining reactions to 200uL with PBS 
8. Centrifuge cells 400 x g for 5 min 
9. Discard supernatant and wash cells twice with chilled FACS (0.5%BSA in PBS) buffer 
10. Bring samples up in 100uL and add 1 ul of FC block to all samples 
11. Incubate for 10 min at room temp 
12. Bring staining reactions to 200uL with FACS buffer 
13. Centrifuge cells 400 x g for 5 min 
14. Discard supernatant and wash cells once with chilled FACS buffer 
15. Bring staining reactions to 100uL with FACS buffer 
16. Add 2 ul of unlabeled pentamer to the appropriate tube 
17. Incubate for 10 min on ice 
18. Wash cells once with FACS buffer and discard supernatant  
19. Add 8ul of APC flourotag to cells 
20. Incubate for 20 min on ice  
21. Wash cells once with FACS buffer and discard supernatant  
22. Resuspend cells in 100uL staining medium containing antibodies (Table 1)  
23. Incubate for 30 min at 4°C in the dark 
24. Bring staining reactions to 200uL with FACS buffer 
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25. Centrifuge cells 400 x g for 5 min 
26. Discard supernatant and wash cells twice with FACS buffer 
27. Discard supernatant and fix cells using 100uL eBioscience FoxP3 Fix/Perm buffer 
28. Incubate 20 minutes on ice in the dark 
29. Add 100uL of eBioscience FoxP3 Perm/Wash buffer to wash 
30. Centrifuge cells 2000 rpm for 5 minutes 
31. Make intracellular staining (ICS) antibody cocktail mix 
32. Discard supernatant and immediately add 100uL of ICS antibody cocktail mix 
33. Incubate for 20-30 minutes on ice in the dark 
34. Add 100uL Perm/Wash buffer to staining reactions to wash 
35. Wash cells 2x times and discard supernatant 
36. Bring reactions to 200uL with FACS buffer 
37. Acquire samples on X50 cytometer at the NIH 
 
Flow Cytometry Analysis. 
 
All statistical analysis was done using Flowjo version 10 software of all FCS files. Briefly, we 
manually gated all T cells subsets, including antigen-specific CD8+ T-cell subsets. We then 
concatenate all downsampled samples together to run UMAP dimensional reduction analysis to 
identify populations that cluster (indication of similarity) and assess heat maps for phenotypes 
of these clusters.  
Results 
Panel Development. Our aim was to develop a panel that encompassed phenotypic markers 
that could be important to understanding HCV pathogenesis. To do so, we added 27 markers 
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that have previously been described to be important for HCV outcome and differentiating T-cell 
subsets (Table 3.1). Optimization of a comprehensive panel involved antibody titrations to 
determine the appropriate dilution in which the negative and positive populations were clearly 
differentiated (Table 3.1). Examples of two antibody titrations included in panel development 
are shown in Supplementary Figure 3.1. After many iterations of our panel, the final developed 
panel is pictured in Figure 3.1A as an N by N plot. This plot is used to visualize every maker in 
the panel against one another to differentiate any spillover that would cause compensation 
issues. Our final panel has minimal spillover and compensation issues.  
Identification of HCV Subjects. The overall goal of the panel was to allow simultaneous analysis 
of multiple interesting markers on HCV-specific T-cells. We used three different class  
pentamers to study the HCV-specific CD8+ T-cell responses in one subject who progresses to 
chronic infection (S29), and one subject who repeatedly clears infection (S553). Both S29 and 
S553 are PWID enrolled in the BBAASH cohort, who were longitudinally followed for over six 
years. S29 was chosen as our chronic control because he is infected with a genotype 1a strain 
and remained chronically infected for over six years (Figure 3.2A). S29 was sampled frequently 
during both acute and chronic infection. In comparison, S553 was acutely infected with a 
genotype 1b virus, but clears infection. S553 is infected with a 1a infection and then 3a 
infection before clearing their second infection. It is possible S553 cleared the 1a infection prior 
to being infected with a 3a genotype, but infrequent sampling made it difficult to deduce. S553 
goes on to clear a genetically distinct 1a infection, and two genetically distinct 2b infections 
(Figure 3.2B).  
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Using the IFN--ELISpot assay we determined peptides recognized by CD8+ T cells at multiple 
sampling visits for both S29 and S553, and designed pentamers using the sequences recognized 
as listed in Table 3.2. Our progressive gating strategy (Figure 3.3A), demonstrates steps taken 
to clearly differentiate the effector memory (TEM), central memory (TCM), naïve (TN), and the 
CD45RA+ effector memory (TEMRA) CD8+ T-cell subsets. Both S29 and S553 had HCV-specific 
CD8+ T-cell responses, and gating was based on a healthy control to eliminate any non-specific 
background staining (Figure 3.3B). Pentamer staining for the other time points are visualized in 
Supplementary Figure 3.2.  
High-Parameter flow Analysis of HCV-Specific CD8+ T-cells in HCV Subjects. Given the multiple 
parameters used to assess differences we performed an unbiased high dimensional analysis 
known as UMAP. Briefly, UMAPs are used to show flow populations that are similar to each 
other, and therefore cluster together. Heat map analysis was performed to globally highlight 
specific markers that were highly expressed in different clusters (Figure 3.4A). S29 clustered 
separately from S553, but interestingly the different time points assayed for S553 clustered 
separately as well. The UMAP heatmap analysis revealed the S29 cluster had higher expression 
of PD-1, TCF1, and CD38 than the S553 clusters, while the S553 T3 cluster had higher expression 
of CD127, Tigit, and CXCR3. We further assessed the expression of common inhibitory markers 
within our HCV-specific CD8+ T-cells, using median mean fluorescence intensities (MFI) (Figure 
3.4B-D). MFI is a useful tool to assess mean fluorescence intensities when there are no clear 
positive and negative populations. PD-1 can have varying degrees of intensities as visualized in 
Figure 3.4B.  PD-1, TCF1, and Tigit were expressed at varying degrees across all time points in 
both S29 and S553. For example, S29 T1 (light red histograms) had high levels of TCF1, Tigit, and 
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PD-1, whereas S553 T2 (orange histogram) had low levels of PD-1, intermediate levels of Tigit, 
and high levels of TCF1 expression (Figure 3.4B-D). There was no significant difference in 
expression of Tim-3, LAG-3, and KLRG1 across both subjects and all time points (Supplementary 
Figure 3.3).  
Next, we assessed the PD-1 and CTLA-4 expression in HCV-specific CD8+ T-cells for S29 T2 and 
S553 T3. These time points were chosen because they had the largest cluster of pentamer 
staining to allow differentiation of markers, and were both in the chronic phase of infection. All 
HCV-specific CD8+ T-cells in S29 were PD-1 positive and CTLA-4 negative, while all HCV-specific 
CD8+ T-cells in S553 were PD-1 and CTLA-4 double negative (Figure 3.5A-B). We then assessed 
the activation state of HCV-specific CD8+ T-cells by expression of CD38 and found S29 had high 
expression of CD38, whereas S553 had low expression of CD38 (Figure 3.5C-D). Antigen-specific 
CD8+ T-cells in S29 expressed low levels of CD127, in comparison to S553 which expressed high 
levels of CD127. Finally, both S29 and S553 had high expression of pentamer positive cells in the 
effector memory population (Figure 3.5E-F).  S553 also had higher expression of pentamer 
positive cells in the TEMRA subset in comparison to S29 (Supplementary Figure 3.4).  
Discussion and Limitations 
HCV remains to be a major public health issue as rates of HCV infection are increasing. Although 
there is a cure for HCV, a prophylactic vaccine has yet to be developed.  The need for a vaccine 
is evident with the high costs of treatment, downstream health complications from chronic 
infection, and the low number of individuals being tested for HCV. Natural infection with HCV 
results in two major outcomes; an individual remains chronically infected or an individual clears 
infection. Given this phenomenon, studying natural HCV infection allows us to understand the 
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innate and adaptive immune mechanisms needed to result in clearance of infection. HCV-
specific CD8+ T-cells play a critical role in clearance as shown previously [111]. Briefly, it was 
shown that CD8+ T-cell depletion in chimpanzees led to persistence, but restoration of CD8+ T-
cells led to rapid clearance of infection. To better characterize human HCV-specific CD8+ T-cells 
we developed a high parameter flow cytometry panel to simultaneously assess many markers 
on T-cells, including inhibitory markers, activation markers, and T-cell subset markers. Our 
developed panel is the most comprehensive flow cytometry panel used in assessing HCV-
specific CD8+ T-cells in chronic versus spontaneous clearers. In chronic infection, we 
demonstrated the upregulation of the inhibitory receptor PD-1. These PD-1 positive HCV-
specific T-cells were also low in CD127 expression as previously described in chronic infection 
with intact antigen [155]. Interestingly, these cells were also high in CD38 expression, a 
phenotype not usually attributed to impaired function of HCV-specific CD8+ T-cells. Conversely, 
S553, had low levels of PD-1 expression, and high frequency of CD127 expression on HCV-
specific CD8+ T-cells, a phenotype previously reported in individuals who clear infection [156]. 
A unique population of HCV-specific CD8+ T-cells in S29 had expression of CD127, PD-1, and 
TCF1, a previously described phenotype in chronic infection consisting of memory-like 
characteristics with the ability to proliferate [157]. Our panel also revealed unique HCV-specific 
CD8+ T-cell populations in both S29 and S553. For instance, S553 had PD-1lo, CD127hi, TCF1hi, 
and CD38lo, CXCR3hi populations that have not previously been reported. This population is 
unique and could play a role in viral clearance. However, further work needs to be done to 
assess this relationship.  
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Development of this panel resulted in limitations, including difficulty detecting OX40 and LAG-3 
expression. Multiple clones on multiple fluorophores were tested, before the final antibodies 
were included in the panel. However, there is still minimal expression of both OX40 and LAG-3 
on CD8+ T-cells. This limitation is a result of high-parameter panels in which spill over is 
inevitable and can make detection of low-expression molecules difficult to detect.  
In conclusion, we have developed a high parameter flow cytometry panel to comprehensively 
assess HCV-specific CD8+ T-cells. This panel identified previously defined populations shown to 
correlate with clearance or persistence. We have also identified novel HCV-specific CD8+ T- cell 
populations, but their importance in clearance versus persistence is yet to be studied. Future 
work involves using this panel to assess additional chronic and spontaneous resolvers to fully 
understand the T-cell phenotypes essential for clearance. This work is important for vaccine 
development because it highlights a possible immune mechanism that can be targeted to lead 













Specificity Dye Dilution Function 
TCF1 BB515 1:20 T-cell Subset (Precursor memory) 
CD11c BB630 1:160 T-cell Subset (integrin) 
TIGIT BB660 1:80 Co-Inhibitory 
CD194 (CCR4) BB700 1:20 Chemokine involved in cell trafficking of 
leukocytes 
CD185 (CXCR5) BB790 1:640 Trafficking and marker of Tfh cells 
CD223 (LAG-3) BV421 1:20 Co-Inhibitory 
CD8 BV510 1:160 Lineage 
CD28 BV570 1:20 Co-Stimulatory 
CD161 BV605 1:40 T-cell Subset and NK cell function 
HLADR BV650 1:80 Activation 
CD134 (OX40) BV711 1:1 Co-Stimulatory 
CD38 BV750 1:40 Activation 
CD27 BV785 1:160 Activation 




CD3 BUV496 1:80 Lineage 
CD25 BUV563 1:160 Lineage 
CD279 (PD-1) BUV661 1:20 Co-Inhibitory 
CD366 (TIM-3) BUV737 1:20 Co-Inhibitory 
CD4 BUV805 1:20 Lineage 
Pentamer APC 1:20 Antigen-Specificity 
CCR5 Ax700 1:40 T-cell Homing 
CD45RA APC Cy7 1:320 Lineage 
CD183 (CXCR3) PE 2:1 Trafficking 
KLRG1 PE-CF594 1:20 Co-Inhibitory 
CD127 (IL-7Rα) PE-Cy5 1:1 Differentiation and memory marker on T-cells 
CD152 (CTLA-4) PE-Cy7 1:20 Co-Inhibitory 
 
Table 3.1: The Optimized 27-color Panel for Flow Cytometry. Dilutions for each marker were 
determined and optimized so each marker in this panel was appropriately expressed, with 
minimal spillover. The fluorophore and function of each marker are listed above. 
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Subject Days post-infection  Pentamer Sequence Time Point 
29 58 CINGVCWTV S29 T1 
  1524 CINGVCWTV S29 T2 
553 1232 CINGVCWTV S553 T1 
  1232 HSKKKCDEL S553 T2 
  1597 ATDALMTGY S553 T3 
  2003 ATDALMTGY S553 T4 
 
Table 3.2: Summary of Subjects and Pentamer Sequence Used for Flow Cytometry. S29 
(chronic) and S553 (reinfected) were selected for our preliminary studies. The pentamer 
















Figure 3.1A: N by N plot of All Markers in 27-Color Flow Panel. NxN plot showing every 
parameter against each other in the developed panel. Note that there are distinct populations 




Figure 3.2: Representative graphs demonstrating the longitudinal history of viremia in 
subjects S29 and S553. A) Log transformed HCV RNA levels are graphed for S29, who remains 
chronically infected with genotype 1a virus for over six years. B) Log transformed HCV RNA 
levels for S553, who repeatedly clears multiple HCV infections of diverse genotypes over six 
years. Each genetically unique infection is color coated, as well as the time points S29 and S553 











Figure 3.3: Staining Pattern for gating, T-cell differentiation characterization, and identifying 
HCV-specific CD8+ T-cells. A) Progressive gating strategy to identify CD4+ and CD8+ T-cell 
populations. Further gating of CD8+ T-cells are shown to identify the major T-cell subsets TCM 
(central memory), TEM (effector memory), TN (naïve), and TEMRA (CD45RA+ effector memory). 
B) Gating of pentamer-positive CD8+ T-cells to identify a clear antigen positive population in 
both S29 and S553. A healthy donor was used as a negative control to ensure gating excluded 













Figure 3.4: High dimensional analysis of HCV-Specific CD8+ T-cells in S29 and S553. A) UMAP 
analysis of HCV-specific CD8+ T-cells in S29 and S553 shows S29 and S553 T-cells cluster 
separately. T-cells from S29 cluster together through all time points, while S553 cluster 
separately for most time points indicating phenotypically unique virus-specific populations in 
each time point. Heatmap analysis shows global expression differences. PD-1, TCF1, and CD38 
have higher expression patterns in S29 while CD127, Tigit, and CXCR3 have higher expression 
patterns in S553. B) Median MFI analysis of PD-1, TCF1, and Tigit of HCV-specific CD8+ T-cells. 
Each time point for S29 and S553 are color coated along with their respective histogram and 


















         













Figure 3.5: HCV-specific CD8+ T-cells diverge in phenotype in S29 and S553. A) Expression of 
PD-1 and B) CTLA-4 on HCV-specific CD8+ T-cells. PD-1 was highly expressed on virus-specific 
CD8+ T-cells in S29. CD38 expression on HCV-specific CD8+ T-cells from C) S29 and D) S553. 
CD38 was highly expressed on virus-specific CD8+ T-cells in S29. CD127 expression on HCV-
specific CD8+ T-cells from E) S29 and F) S553. S553 has high expression of CD127 on virus-
specific CD8+ T-cells.  
Supplementary Figures 
 
Supplementary Figure 3.1: Titration of CD3 and CD4 for the 27-color Flow Panel. A series of 
eight 2-fold dilutions were performed on PBMCs stained with CD3 or CD4 flow antibodies. The 
red box indicates the chosen dilution to include in the panel. 1:20 was chosen for CD4 and 1:40 




Supplementary Figure 3.2: HCV-Specific CD8+ T-cells in S29 and S553. Pentamer staining of 
S29 and S553 at the remaining time points not used in the main analysis. These plots show 
distinct virus-specific populations on CD8+ T-cells. The black box encompasses the pentamer 
positive CD8+ T-cells.  
 
Supplementary Figure 3.3: Median MFI of TIM-3, KLRG1, and LAG3 in S29 and S553. HCV-
specific CD8+ T-cells were analyzed for expression of TIM-3, KLRG1, and LAG3. All time points 
were analyzed to show very low expression of all inhibitory markers on virus-specific T-cells. 
Time points are color-coated with their respective histogram colors.  
 










Supplementary Figure 3.4: HCV-specific CD8+ T-cell phenotype in S29 and S553. Pentamer 
positive CD8+ T-cells were analyzed for the characterization in the T-cell subsets EM, CM, TN, 
and TEMRA. S29 had more virus-specific T-cells with a central memory phenotype, while S553 
had more virus-specific T-cells with both the effector memory and TEMRA phenotype. 



































This thesis presents novel tools to further study immune responses in both HIV-1 and 
HCV infection in PWIDs that are applicable to a wide variety of viral chronic infections.  
In chapter two, we have demonstrated CMPK2 and BCL-G are interferon stimulated 
genes that restrict HIV-1 infection.   RNA interference demonstrated that the anti-HIV-1 effect 
of IFNα could be attributable to both CMPK2 and BCL2L14. The mechanisms underlying how 
these ISGs restrict HIV-1 are unknown, but our efforts have led us to better understand both 
CMPK2 and BCL2L14 in the context of HIV-1 infection. We characterized BCL2L14 as a potential 
gene that promotes CD4+ T cell decline during HIV-1, due to its relationship with apoptotic 
proteins. We also identified various genes in the apoptotic pathway, closely correlated with 
BCL-G expression in HIV-1 positive individuals and persisted after treatment with cART.  This 
research supports the potential use of ISGs and their pathways as targets for small drug 
therapeutics to control HIV-1 infection, particularly those that inhibit HIV-1 infection before it 
integrates into the host DNA.  
These tools are also applicable to a wide range of viral infections with both CMPK2 and 
BCL-G as interferon stimulated genes that are putative restriction factors. More broadly BCL-G 
has a controversial role in apoptosis, and its role in HIV-1 could pose a novel mechanism that 
explains the CD4+ T-cell decline that is seen in the natural progression of HIV-1 infection.   
In chapter three, we developed a novel high-parameter flow cytometry panel to 
longitudinally assess the differences in antigen-specific T cells in individuals who naturally clear 
infection multiple times, in comparison to those who fail to do so.  Since the release of directly 
acting antiviral agents (DAAs), HCV can be cured, but many factors limit the effectiveness of 
73 
 
DAAs in eradicating HCV. As a result, the development of a prophylactic vaccine is critical for 
efforts towards eradicating HCV. Vaccine development has been complicated by the wide 
genetic variability of HCV and the limited characterization of cellular responses important in 
controlling infection.  Given the importance of CD4+ and CD8+ HCV-specific T-cell responses in 
controlling HCV in individuals who become reinfected, better understanding of these T-cell 
responses will help guide effective vaccine design. It is likely that a combination of multiple 
phenotypic markers contributes to the difference in T-cells that either mount control or fail to 
elicit a protective immune response. However, it is unclear which markers and if any in 
combination are the key in control of HCV infection. This research highlights the importance of 
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